|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/21 | |
| A61P 35/00 |
| (11) | Patento numeris | 2621516 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11829825.6 |
| Europos patento paraiškos padavimo data | 2011-09-28 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-08-07 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-06-22 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/053681 |
| Data | 2011-09-28 |
| (87) | Numeris | WO 2012/044684 |
| Data | 2012-04-05 |
| (30) | Numeris | Data | Šalis |
| 389009 P | 2010-10-01 | US |
| (72) |
BAKER, Darren, P., US
JOSEPH, Ingrid, B.J.K., US
WANG, Xinzhong, US
|
| (73) |
Biogen MA Inc.,
250 Binney Street, Cambridge, MA 02142,
US
|
| (54) | INTERFERON-BETA FOR USE AS MONOTHERAPY OR IN COMBINATION WITH OTHER CANCER THERAPIES |
| INTERFERON-BETA FOR USE AS MONOTHERAPY OR IN COMBINATION WITH OTHER CANCER THERAPIES |